Recombinant rat FGF9/GAF protein (ab9745)
Key features and details
- Expression system: Escherichia coli
- Purity: > 95% SDS-PAGE
- Active: Yes
- Suitable for: Functional Studies, SDS-PAGE
Description
-
Product name
Recombinant rat FGF9/GAF protein
See all FGF9/GAF proteins and peptides -
Biological activity
Determined by dose-dependent ability to reduce tetrazolium salt, WST-8, by dehydrogenase activities of BaF3 cells expressing FGF receptors using Cell Counting Kit-8 (CCK-8).
-
Purity
> 95 % SDS-PAGE.
Sterile filtered Greater than 95% pure by HPLC analyses. Endotoxin level is less than 0.1 ng per g (1EU/g). -
Expression system
Escherichia coli -
Protein length
Full length protein -
Animal free
No -
Nature
Recombinant -
-
Species
Rat -
Predicted molecular weight
23 kDa
-
Specifications
Our Abpromise guarantee covers the use of ab9745 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Functional Studies
SDS-PAGE
-
Form
Lyophilized -
Additional notes
mFGF-9 is fully biologically active when compared to standards. The ED50, as determined by the dose-dependent stimulation of thymidine uptake by BaF3 expressing FGF receptors, is less than 0.5 ng/ml, corresponding to a specific activity of >2 X 106 units/mg. Murine FGF-9 exerts full activity on both murine and human cells. For most in vitro applications, FGF-9 exerts its biological activity in the concentration range of 0.1 to 20.0 ng/ml.Previously labelled as FGF9.
-
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
-
ReconstitutionReconstitute using 50ul of sterile H20.
General Info
-
Alternative names
- FGF 9
- FGF-9
- FGF9
see all -
Function
May have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors. -
Tissue specificity
Glial cells. -
Involvement in disease
Defects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness. -
Sequence similarities
Belongs to the heparin-binding growth factors family. -
Post-translational
modificationsThree molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step.
N-glycosylated. -
Cellular localization
Secreted. - Information by UniProt
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (0)
ab9745 has not yet been referenced specifically in any publications.